Drugs / Bispecific antibody for PD-L1 and VEGF-A
Bispecific antibody for PD-L1 and VEGF-A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05142189 | Jun 2022 → Feb 2030 expected | non-small cell lung carcinoma | BioNTech SE | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bispecific antibody for PD-L1 and VEGF-A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05142189 ↗ |
| Modality | Protein / enzyme biologic | “Bispecific antibody for PD-L1 and VEGF-A” NCT05142189 ↗ |
| Route | Intravenous | “Intravenous infusion” NCT05142189 ↗ |